Search research articles
Contact Us
Filters
Showing results (1-10 of 185) with videos related to
Page
of 19
Sort By:
The Oncologist
|
May 9, 2019
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2022
Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade
Valsamo Anagnostou, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2022
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy
Lilit Karapetyan, Jason J Luke
Current Oncology Reports
|
September 11, 2016
Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era
Kevin Wood, Jason J Luke
The Oncologist
|
May 28, 2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma
Jason J Luke, F Stephen Hodi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2011
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma
Jason J Luke, F Stephen Hodi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2022
Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy
Jessica C Hassel, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2023
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade
Richard C Wu, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2023
PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long?
Ryan C Augustin, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2020
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Christopher S Garris, Jason J Luke
Page
of 19
Search research articles
Search
Showing results (1-10 of 185) with videos related to
Sort By:
Page
of 19
The Oncologist
|
May 9, 2019
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2022
Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade
Valsamo Anagnostou, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2022
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy
Lilit Karapetyan, Jason J Luke
Current Oncology Reports
|
September 11, 2016
Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era
Kevin Wood, Jason J Luke
The Oncologist
|
May 28, 2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma
Jason J Luke, F Stephen Hodi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2011
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma
Jason J Luke, F Stephen Hodi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2022
Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy
Jessica C Hassel, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2023
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade
Richard C Wu, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2023
PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long?
Ryan C Augustin, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2020
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Christopher S Garris, Jason J Luke
Page
of 19